6,913 reports of this reaction
3.2% of all CARBOPLATIN reports
#3 most reported adverse reaction
ANAEMIA is the #3 most commonly reported adverse reaction for CARBOPLATIN, manufactured by Accord Healthcare, Inc.. There are 6,913 FDA adverse event reports linking CARBOPLATIN to ANAEMIA. This represents approximately 3.2% of all 214,224 adverse event reports for this drug.
Patients taking CARBOPLATIN who experience anaemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ANAEMIA is moderately reported among CARBOPLATIN users, representing a notable but not dominant share of adverse events.
In addition to anaemia, the following adverse reactions have been reported for CARBOPLATIN:
The following drugs have also been linked to anaemia in FDA adverse event reports:
ANAEMIA has been reported as an adverse event in 6,913 FDA reports for CARBOPLATIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
ANAEMIA accounts for approximately 3.2% of all adverse event reports for CARBOPLATIN, making it one of the most commonly reported side effect.
If you experience anaemia while taking CARBOPLATIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.